{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"153","value":"456"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"85"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Participants in the China population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.","id":"OG000","title":"Atezolizumab + Bevacizumab - China"}],"paramType":"MEAN","populationDescription":"The China PK-evaluable population was defined as all participants in the China population who received any dose of study treatment and who had at least one post-baseline PK sample available.","reportingStatus":"POSTED","timeFrame":"Post-dose on Day 1 of Cycle 1 (cycle length = 21 days)","title":"Maximum Serum Concentration (Cmax) of Atezolizumab in the China Population","type":"SECONDARY","unitOfMeasure":"mcg/mL"}